Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03760575 · ClinicalTrials.gov registry record · Phase 1
Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)
A Phase 1 study of Mesotheliomas Pleural, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT03760575 is a Phase 1 study of Mesotheliomas Pleural that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 20 participants, below the 32-participant average among 4 other Mesotheliomas Pleural trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03760575, a Phase 1 study of Mesotheliomas Pleural, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The study is a single-arm phase I trial to evaluate the safety, feasibility, and preliminary efficacy of the addition of pembrolizumab and image-guided resection to surgical therapy and chemotherapy for malignant pleural mesothelioma (MPM).
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Cisplatin
- PROCEDURE Indocyanine Green (ICG) Image-Guided Surgery
- DRUG Pemetrexed
Study Locations (1)
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-01-10 |
| Est. Completion | 2027-02-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03760575
The ClinicalTrials.gov registry entry for NCT03760575 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 32-participant average among 4 other Mesotheliomas Pleural trials with a reported enrollment target (37% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mesotheliomas Pleural appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT03760575 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03760575 about?
NCT03760575 is a clinical study titled "Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)". The study is a single-arm phase I trial to evaluate the safety, feasibility, and preliminary efficacy of the addition of pembrolizumab and image-guided resection to surgical therapy and chemotherapy for malignant pleural mesothelioma (MPM).
What is the current status of trial NCT03760575?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2023-01-10. Estimated completion is 2027-02-01.
What conditions does trial NCT03760575 study?
This clinical trial studies the following conditions: Mesotheliomas Pleural.
What interventions are being tested in trial NCT03760575?
The interventions under investigation include: Pembrolizumab (DRUG), Cisplatin (DRUG), Indocyanine Green (ICG) Image-Guided Surgery (PROCEDURE), Pemetrexed (DRUG).
Who is sponsoring clinical trial NCT03760575?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03760575 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mesotheliomas Pleural
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
ACTIVE NOT RECRUITING · Phase 1
-
A Study of Sacituzumab Govitecan in People With Mesothelioma
RECRUITING · Phase 2
-
Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.